Inflarx NV (NASDAQ:IFRX) has earned an average recommendation of “Hold” from the eleven brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $6.20.

Separately, Zacks Investment Research cut shares of Inflarx from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

NASDAQ:IFRX traded down $0.10 during trading hours on Thursday, hitting $3.46. The company had a trading volume of 9,098 shares, compared to its average volume of 1,175,168. The company has a market capitalization of $88.28 million, a PE ratio of -2.43 and a beta of -1.27. The stock has a 50-day moving average price of $2.63 and a 200 day moving average price of $6.48. Inflarx has a 52 week low of $2.17 and a 52 week high of $53.10.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new position in Inflarx in the second quarter worth $884,000. Morgan Stanley lifted its position in Inflarx by 454.5% during the 2nd quarter. Morgan Stanley now owns 337,247 shares of the company’s stock valued at $1,066,000 after acquiring an additional 276,424 shares during the period. FMR LLC purchased a new position in Inflarx during the 1st quarter valued at about $9,609,000. Millennium Management LLC boosted its stake in Inflarx by 2,102.2% during the third quarter. Millennium Management LLC now owns 160,521 shares of the company’s stock worth $396,000 after acquiring an additional 153,232 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Inflarx during the second quarter worth about $445,000. Institutional investors own 17.49% of the company’s stock.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Recommended Story: What is the Euro STOXX 50 Index?

Analyst Recommendations for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.